AC方案联合吉非替尼序贯疗法对EGFR基因突变型肺腺癌的控制效果及对Napsin A、RRM1蛋白表达的影响  

Control effect of AC regimen combined with gefitinib sequential therapy on EGFR gene mutant lung adenocarcinoma and its influences on the expression of Napsin A and RRM1 protein

作　　者：刘郑生 温婷 LIU Zhengsheng;WEN Ting(Baoji People's Hospital,Baoji 721000,China)

机构地区：[1]宝鸡市人民医院,陕西宝鸡721000

出　　处：《临床医学研究与实践》2021年第28期75-77,共3页Clinical Research and Practice

摘　　要：目的探讨AC方案联合吉非替尼序贯疗法对表皮生长因子受体(EGFR)基因突变型肺腺癌的控制效果及对Napsin A、RRM1蛋白表达的影响。方法将2017年10月至2019年10月收治的70例EGFR基因突变型肺腺癌患者以随机数字法分为对照组和观察组,各35例。对照组采用吉非替尼治疗,观察组采用AC方案联合吉非替尼序贯疗法治疗。比较两组的治疗效果。结果观察组的临床控制率为80.00%,高于对照组的57.14%(P<0.05)。两组的恶心呕吐、纳差、白细胞减少、血红蛋白降低、肝损伤、肾损伤及血小板减少发生率无显著差异(P>0.05)。治疗后,观察组的Napsin A、RRM1蛋白阳性表达率均低于对照组(P<0.05)。观察组1年无进展生存期为(9.48±1.86)个月,长于对照组的(6.83±1.54)个月(P<0.05)。结论AC方案联合吉非替尼序贯疗法治疗EGFR基因突变型肺腺癌效果显著,可控制疾病进展,也能降低Napsin A、RRM1蛋白阳性表达率,且不良反应可控,值得推广。Objective To explore the control effect of AC regimen combined with gefitinib sequential therapy on epidermal growth factor receptor(EGFR)gene mutant lung adenocarcinoma and its influences on the expression of Napsin A and RRM1 protein.Methods A total of 70 patients with EGFR gene mutant lung adenocarcinoma admitted from October 2017 to October 2019 were divided into control group and observation group by random number method,with 35 cases in each group.The control group was treated with gefitinib,and the observation group was treated with AC regimen combined with gefitinib sequential therapy.The therapeutic effects of the two groups were compared.Results The clinical control rate of the observation group was 80.00%,which was higher than 57.14%of the control group(P<0.05).There were no significant differences in the incidences of nausea and vomiting,poor appetite,leukopenia,decreased hemoglobin,liver injury,kidney injury and thrombocytopenia between the two groups(P>0.05).After treatment,the positive expression rates of Napsin A and RRM1 protein in the observation group were lower than those in the control group(P<0.05).The 1-year progression-free survival in the observation group was(9.48±1.86)months,which was longer than(6.83±1.54)months in the control group(P<0.05).Conclusion AC regimen combined with gefitinib sequential therapy is effective in the treatment of EGFR gene mutant lung adenocarcinoma,it can control the disease progression,reduce the positive expression rates of Napsin A and RRM1 protein,with controllable adverse reactions,which is worthy of popularization.

关 键 词：AC方案 吉非替尼 序贯疗法 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]